US EditionPublished • loading... • Updated
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick
Revolution will now explore daraxonrasib’s potential as a monotherapy and in combination with chemotherapy in late-stage PDAC trials.The post Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
